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Abstract 
Gastrin releasing peptide (GRP) receptor (GRPR), a bombesin family receptor, is 
overexpressed in many cancers including breast, prostate, pancreatic and lung. The targeting 
of therapeutics to GRPR can be achieved using the full-length (14 amino acid) GRP analogue 
Bombesin (BBN) or the truncated BBN(6-14) sequence, both of which bind GRPR with high 
affinity and specificity. In this study, we have investigated the level of GRPR expression in 
various cancerous (Caco-2, HeLa, LNCap, MDA-MB-231, and PC-3) and non-cancerous 
(WPMY-1) cell lines using a western blotting approach. Such information is currently 
lacking in the literature, and is therefore of importance for the in vitro assessment of GRPR 
targeted therapeutics. Of the cell lines assessed, the PC-3 (prostate cancer) and Caco-2 (colon 
cancer) cell lines demonstrated the highest and lowest levels of GRPR expression 
respectively. Using this information, we further investigated the cellular uptake of 
carboxyfluorescein-labelled BBN and BBN(6-14) peptides by flow cytometry and confocal 
microscopy using cell lines that express GRPR (Caco-2, HeLa, PC-3). The uptake of each of 
these peptides was similar, suggesting that the shorter BBN(6-14) peptide is sufficient for 
GRPR targeting. Further, the uptake of these peptides could be inhibited by competition with 
unlabelled BBN peptides, suggesting their cellular uptake is GRPR-mediated, while the level 
of BBN uptake (as measured by flow cytometry) was found to be directly proportional to the 
level of GRPR expression. Overall, the information obtained from these studies provides 
useful information for the in vitro assessment of GRPR targeted therapeutics. 
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1 Introduction 
Cancer cells display a set of heterogeneous characteristic features including uncontrolled cell 
division, clonal expansion, intravasation and extravasation in the blood and lymphatic 
vessels, and metastasis to invade different tissues.
1
 Growth factor receptors, which are 
expressed on the cell surface and in the cytoplasm of tumours, are associated with tumour 
development, progression, angiogenesis and metastasis.
2, 3
 Overexpressed growth factor 
receptors are considered to be tumour biomarkers, which can be used as targets for tumour 
diagnosis and/or therapeutic targeting. Examples include vascular endothelial growth factor 
(VEGF),
4
 epidermal growth factor (EGF),
5
 and fibroblast growth factor (FGF),
6
 which have 
been targeted by anticancer therapies against bladder, prostate, colorectal and breast cancers. 
 
Over the past few decades, research has suggested that bombesin (BBN) family peptides act 
as growth factors for various cancers including breast, colon, prostate and small cell lung 
cancer.
2
 Bombesin is a tetradecapeptide which was first isolated from the skin of the 
Bombina bombina frog in 1972.
7
 Since its initial isolation, extensive investigations have been 
conducted, which have provided valuable insights into the function of BBN and its 
corresponding receptors.
8
 Three types of mammalian BBN receptors have been identified: 
gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin 
receptor subtype-3 (BRS-3). Each of these receptors belongs to the G-protein coupled 
receptor super family.
9
  
 
Bombesin and its mammalian counterpart gastrin-releasing peptide (GRP) have structural and 
functional similarities.  The 27-amino acid long peptide, GRP, was first identified from 
porcine gut in 1979.
10
 Both BBN and GRP share a homologous C-terminal seven amino-acid 
long sequence Trp-Ala-Val-Gly-His-Leu-Met-NH2,
8
 which is important for receptor binding 
and internalisation.
9
  Due to this similarity, BBN and GRP exert similar physiological effects. 
For example, both peptides function as a gastrointestinal hormone and as a neurotransmitter.
8, 
11
 In addition, they are both mitogens, and function as autocrine growth factors for tumour 
cells.
8, 12, 13
  
 
The GRP receptor is overexpressed in a wide range of cancers, including: glioblastomas, 
small cell lung, gastric, pancreatic, prostate, breast, cervical, and colon cancers, whereas 
NMBR and BRS-3 are expressed in a limited number of carcinomas.
14-17
 Because their 
  
 
 
receptors are overexpressed on various tumours, in addition to their ability to internalise 
GRP-targeted species, BBN and GRP have been investigated as targeting ligands for the 
diagnostic imaging of tumour cells and for tumour-targeted delivery of therapeutics.
14, 16, 18
 
For example, assorted in vivo and in vitro studies have demonstrated high uptake of bombesin 
peptide analogues by tumour cell lines including the PC-3 and DU145 prostate cancer cell 
lines;
15, 19
 the MDA-MB-231 and T-47-D breast cancer cell lines;
8, 20
 and the HeLa cervical 
cancer cell line.
21
 While GRPR agonists have demonstrated the capacity to target GRPR, with 
subsequent cellular uptake, GRPR antagonists show little to no internalisation following 
GRPR binding.
22
  
 
In the present study, we have investigated BBN, a native GRPR agonist, as a GRPR targeting 
ligand that would be useful for the delivery of therapeutics that feature an intracellular site of 
action, particularly for therapeutics that display poor cellular uptake on their own. It has been 
reported that the C-terminal seven to nine amino acids of BBN are necessary for high affinity 
binding to GRPR and for receptor mediated responses.
15, 23
 Therefore, we have produced a 
BBN peptide library that includes both the full length BBN peptide and a truncated BBN 
peptide [BBN(6-14)] to investigate whether the shorter, more serum stable,
24, 25
 and more 
readily synthesised BBN(6-14) peptide is as effective for GRPR targeting as the full length 
peptide. Further, the capacity for these peptides to be internalised by receptor mediated 
cellular internalisation has been studied using 5(6)-carboxyfluorescein fluorescently tagged 
BBN peptides. Prior to evaluating the cellular uptake of each analogue, the level of GRPR 
expression in a library of cancerous (Caco-2, HeLa, LNCap, MDA-MB-231, and PC-3) and 
immortalised primary cell lines (WPMY-1) was evaluated by western blotting. Quantitative 
(flow cytometry) and qualitative (confocal microscopy) cell uptake studies were then 
conducted to evaluate the level of cellular internalisation and the intracellular localisation of 
each BBN peptide. To evaluate the mechanism of internalisation competitive, and 
temperature dependent cell uptake studies were conducted. A major aim of this study was to 
compare the capacity to target GRPR expressing cancer cell lines using BBN peptides as a 
means to improve the targeted delivery of anticancer therapeutics. Toward this goal, a 
comparison of cellular uptake in breast (MDA-MB-231), colon (Caco-2), prostate (PC-3) and 
cervical cancer (HeLa) cell lines was performed using both BBN peptide analogues. 
  
 
 
 
Figure 1. Library of BBN peptide analogues. (BBN: Bombesin peptide, FAM: 5(6)-
carboxyfluorescein) 
  
2 Results and discussion 
2.1 BBN Peptide synthesis and characterisation 
Each peptide (1-4) was successfully synthesised using manual solid phase peptide synthesis. 
The fluoresecent tag 5(6)-carboxyfluorescein (FAM), was coupled to the N-terminus of 
peptides 1 and 2 through a lysine spacer to produce compounds 3 and 4 using 1-
hydroxybenzotriazole (HOBt) and N,N’-diisopropylcarbodiimide (DIC) as coupling reagents. 
Coupling was performed in the dark to minimise photo bleaching, followed by the removal of 
any ester linked FAM by repeateted  20% piperidine washing (5 min each cycle) until no 
further color was observed when washed. The peptides were cleaved from the resin using 
trifluoroacetic acid (TFA) in the presence of 2.5 % 1,2-ethanedithiol (EDT) to minimize 
methionine oxidation to methionine sulfoxide.
26
 The crude peptides were purified by reversed 
phase-high performance liquid chromatography (RP-HPLC) to > 99% purity using 
water/acetonitrile gradients (Table 1). The purified fractions were lyophilised to yield the 
final pure compounds 1-4, which were characterised by RP-HPLC and electrospray 
ionization-mass spectroscopy (ESI-MS) (Supplementary Fig. 1). Purification and 
characterisation data (RP-HPLC and MS) are presented in Table 1.  
 
 
 
  
 
 
Table 1  
Summary of purification yields and characterisation data (RP-HPLC and ESI-MS) for the 
peptide library 
Compound 
no. 
MW 
(Da) 
Purity RP-HPLC retention time a 
(gradient)b 
ESI-MS 
    Protonation 
state 
Calculated  Found 
1 1054.24 >99% 17.3 min (0-80% solvent B) 
24.1 min(15-35% solvent B) 
[M+H]+ 
[M+2H]2+ 
1055.2 
528.1 
1055.1 
528.6 
2 1619.87 >99% 18.2min(0-80% solvent B) 
26.8min(15-35% solvent B) 
[M+H]+ 
[M+2H]2+ 
1620.8 
810.9 
1620.0 
811.1 
3 1540.72 >99% 20.0 min (0-80% solvent B) 
25.1min(20-45% Solvent B) 
[M+H]+ 
[M+2H]2+ 
[M+3H]3+ 
1541.7 
771.3 
514.5 
1541.9 
771.4 
514.9 
4 2123.38 >99% 19.6min (0-80% solvent B) 
21.4min(25-40% solvent B) 
[M+2H]2+ 
[M+3H]3+ 
[M+4H]4+ 
1062.6 
708.7 
531.8 
1062.0 
709.0 
532.0 
a
 HPLC conditions: 1 mL/min flow rate, 214 nm detection, Vydac C18 column (218TP54,  
4.6 mm × 250 mm, 5 µm) 
b All the gradients were run over 30 min using solvent A: 0.1% (v/v) TFA-H2O; solvent B: 90% (v/v) MeCN-
0.1% (v/v) TFA-H2O.   
 
2.2 Analysis of GRPR expression by western blotting 
Western blotting was performed to investigate the level of GRPR expression in various 
human tumour-derived (HeLa, PC-3, MDA-MB-231,  LNCaP, and Caco-2) and immortalized 
non-tumour-derived (WPMY-1) cell lines. Cell lysates were prepared in 
radioimmunoprecipitation assay (RIPA) buffer, and the protein content for each group 
quantified using a bicinchoninic acid (BCA) assay. Equivalent amounts (15 µg/lane) of total 
protein from each cell line were separated by SDS-PAGE on a 10% gel, electrotransferred 
onto a PVDF membrane, and probed using a polyclonal rabbit α-GRPR antibody (Abcam 
ab39963). GRPR bands were then detected using enhanced chemiluminescence (ECL) after 
probing with a goat α-rabbit IgG-peroxidase conjugate (Sigma A6154) secondary antibody. 
Caco-2 cells were used as a positive control for GRPR expression, as recommended by the 
antibody manufacturer, with glyceraldehyde-3-phosphate dehydrogenase (GADPH) staining 
used as a loading control.
27
 
 
  
 
 
Each of the cell lines tested was observed to express GRPR by western blotting (Fig. 2A). 
The highest level of GRPR expression was observed in the PC-3 prostate cancer epithelial 
cell line, with the Caco-2 colon cancer epithelial cell line demonstrating the lowest level of 
GRPR expression (Fig. 2A). The level of GRPR expression in PC-3 prostate cancer cells was 
also compared to other prostate-derived cell lines including the androgen-sensitive human 
prostate adenocarcinoma cell line LNCaP and the transformed human non-tumour-derived 
prostate myofibroblast  cell line WPMY-1. This comparison demonstrated the GRPR 
expression level in PC-3 cells was significantly higher (4.6-fold higher than Caco-2 cells) 
than observed in LNCaP (1.7-fold higher than Caco-2 cells) or WPMY-1 cell lines (2.2-fold 
higher than Caco-2 cells) (Fig. 2B). In addition, the GRPR expression level in HeLa human 
cervical adenocarcinoma and MDA-MB-231 human breast invasive ductal carcinoma cell 
lines were also assessed. These cell lines exhibited GRPR expression levels in between PC-3 
and LNCaP cells (3- and 2.6-fold higher than Caco-2 cells respectively). Overall, this data 
provides important information relating to the expression levels of GRPR in cultured human 
cell lines, which is lacking in the literature, and will prove useful for the selection of 
appropriate cell lines for in vitro assessment of GRPR targeted therapeutics.  
 
 
 
Figure 2. (A)Western blot analysis of GRPR expression in six different cell lines. Data are 
representative of at least two independent experiments. GADPH is used as a loading 
control.(B) The band density was quantified by densitometry. Data is presented as the fold 
increase in GRP band density in comparison to the Caco-2 cell group. 
 
2.3. Analysis of the cellular uptake of BBN peptides by flow cytometry 
In order to evaluate how effectively BBN peptides are internalised by GRPR expressing cells, 
the cellular uptake of fluorophore-labelled BBN peptides 3 and 4 was evaluated by flow 
  
 
 
cytometry in PC-3 cells at three different concentrations (1, 5, and 10 μM). Trypan blue was 
used to quench any fluorescence associated with surface bound peptides prior to analysis by 
flow cytometry (with the results reported as intracellular fluorescence in Fig. 3) in order to 
differentiate between peptides that are associated with the surface of PC-3 cells, and peptides 
that were internalised.
28
 This experiment demonstrated that the percentage of PC-3 cells 
containing internalised BBN peptides 3 or 4 increased as the concentration of each peptide 
was increased (from 1.76% to 29.8%  and  from 1.86% to 29.7% at 1 and 10 µM for both 
compound 3 and 4, respectively), with comparible results observed at each tested 
concentration for peptides 3 and 4 (p > 0.05) (Fig. 3A). This data indicated that the truncated 
BBN(6-14) peptide 3, which is easier and less expensive to synthesize in comparison to the 
full-length BBN peptide 4, would be  preferable for incorporation into GRPR-targeted 
delivery systems. 
 
 
 
  
 
 
 
Figure 3. Cellular uptake of FAM-labelled BBN peptides 3 and 4 in PC-3 cells as measured 
by flow cytometry. The effect of: (A) BBN peptide concentration (1, 5, and 10 μM); (B) 
temperature (4 °C vs. 37 °C; 5 μM BBN peptides); and (C) competition with a 10-fold excess 
of peptides 1 or 2 over peptides 3 or 4 (5 μM) respectively. Untreated PC-3 cells were used as 
a negative control (Neg. Ctl.). Data is presented as the mean (± SD) percent FAM-positive 
PC-3 cells based on total cellular or intracellular fluorescence after 4 h incubation for 
triplicate samples.  
 
To gain additional insight into the mechanism of cellular uptake, the cell uptake experiment 
was repeated at 4 °C, a temperature at which energy-dependent endocytosis is inhibited.
29
 
Comparing the percentage FAM-positive cells after incubating PC-3 cells with peptides 3 or 
4 at 4 °C and 37 °C revealed that the cellular uptake of both peptides was significantly 
reduced at 4 °C (p < 0.01; Fig. 3B). The percent FAM-positive cells ranged from 20-22% for 
  
 
 
each peptide at 37 °C, and were reduced to 2-4% at 4 °C, suggesting that BBN cellular uptake 
is predominantly associated with energy dependent pathways. 
 
2.4 Competative cell uptake study 
Because fluorescein analogs have been demonstrated to be internalised by cultured cells,
30
 
including conjugates with high molecular weight polymers,
31, 32
 we wanted to demonstrate 
that the observed internalisation of peptides 3 and 4 was due to BBN and not the FAM-label. 
This was achieved by conducting the uptake assay in PC-3 cells with peptides 3 or 4 (5 μM) 
in the presence of a 10× excess of the unlabelled BBN peptides 1 or 2. If the BBN peptides 
were responsible for cellular uptake, rather than the FAM-label, the excess of peptides 1 or 2 
would compete for uptake, and a large reduction in the uptake of 3 or 4 would be observed by 
flow cytometry. This outcome was observed, with the incubation of PC-3 cells with FAM-
labelled peptides 3 and 4 exhibiting only 4 and 2% FAM-positive cells respectively in the 
presence of a 10× excess of peptides 1 or 2 (Fig. 3C). In comparison, where PC-3 cells were 
not exposed to peptides 1 or 2, 47 and 42% FAM-positive cells respectively were observed 
(Fig. 3C). This experiment strongly supported the hypothesis that cellular uptake of peptides 
3 and 4 was due to BBN, and not the FAM-label. In addition, since the uptake process was 
energy dependent, and could be competed with BBN peptides, this data suggested that the 
uptake of peptides 3 and 4 was associated with BBN receptors. The data also demonstrated 
that N-terminal modification of BBN peptides is compatible with BBN receptor targeting and 
cellular uptake, and thus may serve as a modification site for targeting therapeutics to cells 
that overexpress GRPR. 
 
2.5 Comparing the uptake of bombesin peptides in different GRPR-expressing cell lines 
In this report western blotting was used to assess the level of GRPR expression in a library of 
different cultured cell lines. Such information is currently lacking in the literature, and 
provides an important resource for designing in vitro experiments to evaluate GRPR targeted 
delivery systems. However, it is curently unknown if GRPR expression levels alone directly 
correlate with BBN peptide uptake levels in different cell lines. For this reason, we wanted to 
compare the level of FAM-labelled BBN peptide uptake to the level of GRPR expression 
observed by western blotting. For this purpose we compared the uptake of peptides 3 and 4 
(at 5 μM concentration) in three different human tumour cell lines: Caco-2 (colon epithelial), 
HeLa (cervical epithelial), and PC-3 (prostate epithelial), by flow cytometry. Of these cell 
lines, PC-3 cells demonstrated the highest uptake, with 47 and 50% of PC-3 cells 
  
 
 
demonstrating uptake of peptides 3 and 4 respectively (Fig. 4). In comparison, Caco-2 cells 
demonstrated the lowest uptake (5 and 10%), and HeLa cells showed intermediate uptake (16 
and 25%) (Fig. 4). This data was in direct agreement with the GRPR expresion levels 
detected by western blotting of lysates for each of the assessed cell lines (Fig. 2A), and thus 
suggests that the level of BBN peptide uptake is proportional to the level of GRPR 
expression. As such, BBN peptides may prove useful for targeted prostate cancer therapies. 
 
 
Figure 4. Comparing the cellular uptake of FAM-labelled BBN peptides 3 and 4 (at 5 μM 
concentration) in PC-3, HeLa, and Caco-2 cells. Data is presented as the mean percentage ± 
SD (n = 3) of FAM-positive PC-3 cells based on intracellular fluorescence after 4 h 
incubation for repeated experiments.  
 
2.6 Confocal imaging of the internalisation of FAM-labelled BBN peptides 3 and 4 in 
PC-3 cells 
To provide additional supporting evidence for the uptake of FAM-labelled BBN peptides 3 
and 4 in PC-3 cells, live cell confocal microscopy was used to detect internalised peptides 
and to probe their subcellular localisation. For this experiment, the cells were incubated for 4 
h with peptides 3 or 4 at 5 μM concentrations, washed, and stained with: Trypan blue to 
quench surface-associated fluorescence; Hoechst 33342 to label the nucleus; and 
LysoTracker
®
 Red DND-99 to label endo(lyso)somes. Intracellular FAM-associated 
fluoresence was observed at 5 μM concentration for both peptides 3 and 4, with fluorescence 
distributed throughout the cytoplasm (Fig. 5). The presence of punctate staining, colocalised  
with the LysoTracker dye (which stains acidic organelles, i.e. endo(lyso)somes)
33
 suggests 
that BBN peptides are likely internalised by an endocytic pathway, with some entrapment in 
endosomes. Overall, this data demonstrates that the BBN peptides can be internalised by PC-
3 cells, validating the results of our flow cytometry cellular uptake experiments. 
 
  
 
 
 
Figure 5. Live-cell confocal imaging of the uptake and subcellular localisation of FAM-
labelled BBN peptides 3 or 4 (at 5 µM concentration) after 4 h incubation with PC-3 cells. 
Untreated PC-3 cells were used as a negative control (neg. ctl.). Imaging was performed at 
63× magnification, using an oil emersion lens. 
 
3. Conclusion 
The tissue-specific targeting of therapeutic molecules provides a useful means to improve 
drug efficacy by enabling reductions in the dose of therapeutic molecules that are delivered, 
and offering the potential to reduce adverse effects. These advantages of targeted drug 
delivery are of immense interest for the treatment of various cancers. Herein, we aimed to 
characterise the potential of GRPR, which is overexpressed on many types of tumours, to be 
targeted by BBN peptides in order to improve the targeted delivery of anticancer therapeutics. 
A key finding from this work was the evaluation of GRPR expression on a library of different 
cultured cancerous (Caco-2, HeLa, MDA-MB-231, and PC-3) and non-cancerous (WPMY-1) 
cell lines. This information indicated that of these cell lines, PC-3 cells demonstrated 
  
 
 
significantly higher overexpression of GRPR than the other assessed cell lines, with Caco-2 
cells demonstrating the lowest GRPR expression. Using this information, the capacity for 
wildtype BBN and truncated BBN(6-14) peptides to act as ligands for GRPR overexpressing 
cell lines was assessed. In these experiments the level of BBN peptide uptake was found to 
positively correlate with the measured level of GRPR expression in each cell line assessed. 
Further, both BBN analogues (3 and 4) were observed to exhibit similar internalisation by 
flow cytometry and confocal microscopy. This data therefore suggests that the truncated 
BBN(6-14) peptide, owing to its shorter sequence, would be preferable for incorporation into 
GRPR targeted drug delivery systems. Finally, the ability to competitively inhibit the uptake 
of labelled BBN peptides with unlabelled BBN peptides or reduced temperatures suggested 
that the uptake of these peptides was through GRPR rather than non-specific mechanisms. 
Overall, the information gained herein on GRPR expression levels and the uptake of BBN 
peptides in various cancerous and non-cancerous cell lines will prove of great utility for the 
engineering of GRPR targeted drug delivery systems, and for the in vitro assessment of their 
targeting capacity. 
 
4.1 Experimental 
4.1 Materials 
All chemicals used were of analytical grade or equivalent, unless otherwise noted. Rink 
amide p-MBHA resin (100-200 mesh: 0.36 mmol/g),  N,N-dimethylformamide (DMF), 
piperidine and trifluoroacetic acid (TFA) were obtained from Merck Millipore (Kilsynth, 
VIC, Australia). Fmoc (Fluorenylmethoxycarbonyl)-L-amino acids and 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid  
hexafluorophosphate (HATU) were purchased from Mimotopes (Clayton, VIC, Australia). 
N,N-Diisopropylethylamine (DIPEA), and L-pyroglutamic acid were purchased from Sigma-
Aldrich (Castle Hill, NSW, Australia). RPMI-1640 medium, Dulbecco’s modified Eagle’s 
medium (DMEM), Foetal Bovine Serum (FBS), and Opti-MEM
®
 I reduced serum medium 
were purchased from Gibco (Mulgrave, VIC, Australia). Fmoc-Lysine(ivDde)-OH was 
bought from ChemPep inc. (Wellington, FL, USA). YoYo-1, 1kb Plus DNA ladder, Hoechst 
33342, LysoTracker DND 99, Lipofectamine
®
 LTX with Plus™ reagent, and FluoroBrite™ 
DMEM medium were obtained from Invitrogen, Life technologies. (Mulgrave, VIC, 
Australia). All other reagents were purchased from Sigma Aldrich at the highest available 
purity. 
  
 
 
 
4.2 Equipment 
Analytical RP-HPLC analysis was conducted using a Vydac C18 analytical column 
(218TP54, 5 µm, 4.6 x 250 mm) at 1 mL/min flow rate with detection at 214 nm using linear 
gradients  over 30 min as described in table 1. Preparative HPLC was performed using a 
Vydac C18 preparative column (218TP1022, 10 µm, 22 x 250 mm) at 20 mL/min with 
detection at 214 nm. All purifications were performed using linear gradients of solvent A 
[0.1% (v/v) TFA-H2O] and solvent B [90% (v/v) MeCN-0.1% (v/v) TFA-H2O] over 30 min. 
Electrospray ionization-mass spectrometry (ESI-MS) was performed on a Perkin Elmer-Sciex 
API3000 triple quadrupole instrument using Analyst 1.4 software (Applied Biosystems - 
MDS Sciex, Framingham, MA, USA). Confocal microscopy was performed using Zeiss LSM 
710 confocal microscope. Data were analysed in Image J software. Flow cytometry was 
performed on a BD Accuri C6 flow cytometer (BD; New Jersey, USA). 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
4.3 Solid phase peptide synthesis 
Peptides 1-4 (Fig. 1) were prepared by stepwise Fmoc-solid phase peptide synthesis
34
 on 
Rink amide 4-methylbenzhydrylamine (MBHA) resin (100-200 mesh, 0.38 mmol/g) at 0.125 
mmol scale. Fmoc removal was achieved using 20% (v/v) piperidine in DMF for 3 × 5 min at 
RT. Fmoc-amino acids (4.2 eq to resin) were activated with 0.5 M HATU in DMF (4 eq) and 
DIPEA (6 eq) and coupled at RT for 30 min per cycle. A Kaiser test
35
 was performed after 
each amino acid coupling to evaluate coupling efficiency. Where this test demonstrated the 
presence of free amines, the amino acid was recoupled. L-Pyroglutamic acid (4.2 eq to resin) 
was coupled at RT using 0.5 M HOBt (4 eq) and DIC (4 eq) in DMF, with 2 min 
preactivation at 4 °C  followed by 15 min rotation at RT before its addition to the resin for the 
synthesis of wild type bombesin (2). For the synthesis of  fluorophore-labelled peptides (3 
and 4), 5(6)-carboxyfluorescein (2 eq) was coupled through a lysine spacer to peptides 1 and 
2 using 0.5 M HOBt (2 eq) and DIC (2 eq) in DMF, with 15 min preactivation as above. The 
coupling was performed overnight, in the dark to minimize photobleaching. Each peptide was 
cleaved from the resin using TFA/EDT/H2O/triisopropylsilane (TIPS) (94/2.5/2.5/1) for 4 h 
at RT. The peptides were then precipitated using ice-cold diethyl ether, pelleted by 
centrifugation, dissolved in 1:1 MeCN-H2O containing 0.1% (v/v) TFA, and lyophilised to 
yield crude peptides 1-4. 
 
4.4 Purification and characterisation 
  
 
 
Each crude peptide was purified by RP-HPLC on a Vydac C18 column (218TP1022, 22 mm 
x 250 mm) at 20 mL/min using solvent B gradients over 30 min (Table 1) with detection at 
214 nm. Each fraction was analysed for purity by analytical HPLC on a Vydac C18 column 
(218TP54, 4.6 mm × 250 mm, 5 µm) using the same gradient over the same duration used for 
purification. Fractions that contained pure peptide were combined and lyophilised to yield 
pure peptides 1-4. Each peptide was characterised by RP-HPLC for purity and ESI-MS for 
identity (Table 1). 
 
4.5 Cell culture 
Human prostate cancer cell lines PC-3, and LNCaP, and the non-cancerous prostate cell line 
WPMY-1  were cultured in RPMI-1640, supplemented with 10% FBS. Human breast cancer 
cell line MDA-MB231 was cultured in RPMI-1640, supplimented with 10% FBS and 8 mg/L 
insulin (Actrapid
®
 Neutral insulin 100 IU/ml, Novo Nordisk). The human cervical cancer cell 
line HeLa and colon cancer cell line Caco-2 were cultured in Dulbecco's Modified Eagle's 
medium (DMEM), supplemented with 10% FBS and 1% non-essential amino acids. All cells 
were cultured in T-75 flasks at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. All 
cell lines were harvested at confluence and verified by short tandem repeat (STR) profiling 
using a Promega Cell ID kit. 
 
4.6  Western blotting 
Various cancerous (Caco-2, HeLa, LNCaP, MDA-MB-231 and PC-3) and non-cancerous 
(WPMY-1) cell lines were collected on ice after washing with ice-cold PBS, followed by 
scraping of adherent cells into 5 mL of ice-cold PBS. The cell suspensions were then 
collected into a 15 mL conical tube, and pelleted (1000 RPM, 5 min, 4 °C). The supernatant 
was then discarded and the cells were resuspended in 0.5 mL RIPA buffer (150 mM NaCl, 1 
% IGEPAL CA-630, 0.5 % sodium deoxycholate, 0.1 % SDS, 50 mM Tris, pH 8.0) and 
gently aggitated for 30 min at 4 °C. The cell suspensions were then transferred into 
microcentrifuge tubes, pelleted (12k RPM, 10 min, 4 °C), the supernatant collected, and the 
protein content of the supernatant determined using a BCA assay against a bovine serum 
albumin (BSA) standard curve. Equal amounts (15 μg/lane) of protein from each cell line 
were then loaded onto a 10 % reducing SDS-PAGE gel and run at 100 V for 10 min and then 
150 V until the loading dye reached the end of the gel. The proteins were then 
electrotransferred to PVDF membrane (0.2 m pore size) using Towbin buffer (25 mM  Tris 
  
 
 
base, 192 mM Glycine containing 10% MeOH) at 100V for 1 h at 4 °C. The membrane was 
blocked with 5 % (w/v) skim milk powder in TBS-T (20 mM Tris base, 150 mM NaCl 
containing 0.1 % Tween, pH 7.6) for 1 h at RT, and subsequently probed with polyclonal 
rabbit α-GRPR antibody (Abcam ab39963) diluted 1:300 in 5 % (w/v) skim milk powder in 
TBS-T for 1 h at RT. The membrane was then washed for 3 × 5 min with TBS-T, followed 
by probing with goat α-rabbit IgG-peroxidase conjugate (Sigma A6154) secondary antibody 
diluted 1:15000 in 5 % (w/v) skim milk powder in TBS-T for 1 h at RT. The membrane was 
then washed for 3 × 5 min with TBS-T, followed by detection using ECL prime (GE 
Healthcare) enhanced chemiluminescence reagent using a Bio-Rad ChemiDoc™ Touch 
Imaging System. Visualization of protein transfer, and the GAPDH loading control
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 was 
performed using coomassie R-250 staining of the PVDF membrane. 
 
4.7 In vitro cellular uptake experiments 
4.7.1 Flow cytometry quantification of cellular uptake 
Twenty-four hours prior to the study, PC-3 cells were seeded into a 48 well plate at a density 
of 4 × 10
4
 cells/well and cultured as previously described. Upon reaching ~80 % confluence, 
the cells were washed with phosphate buffered saline (PBS) and  then incubated with 200 µL 
/well  Opti-MEM
®
 I reduced serum medium containing 0, 1, 5 and 10 µM of fluoroscently-
labelled   peptides (3 or 4) for 4 h at 37 °C. The cells were then washed three times with 2 % 
(v/v) FBS in PBS (250 µL vol/wash), followed by trypsinisation with 50 μL/well of 
TrypLE
TM 
Express (1) for 5-7 min at 37 °C. Subsequently 250 μL of 2 % (v/v) FBS in PBS 
was added to each well, and the cell suspension was transferred into a microcentrifuge tube. 
To quench any cell surface bound fluorescence, the cells were treated with trypan blue to 0.1 
% final concentration 2 min prior to analysis by flow cytometry (BD Accuri C6 
flowcytometer, 488 nm excitation and 515-545 nm emission filter). Each assay was carried 
out in triplicate and 10,000 events were collected. 
 
4.7.2 The effect of temperature on cellular uptake 
To further investigate the mechanism of uptake for peptides 3 and 4, energy-dependant 
endocytosis was inhibited by conducting the uptake assay 4.7.1 at 4 °C, and comparing the 
results with uptake at 37 °C using flow cytometry. For the 4 °C group, the cells were 
incubated at 4 °C for 30 min prior to performing the uptake experiment.
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4.7.3 Comparing bombesin uptake in Caco-2, HeLa, and PC-3 cells 
The uptake of fluorophore-labelled bombesin peptides 3 and 4 were compared in Caco-2, 
HeLa, and PC-3 cell lines. Each cell line was seeded into 48-well tissue culture plates at a 
cell density of 2 × 10
4 
cells/well for Caco-2 and HeLa cells, and 4 × 10
4 
cells/well for PC-3 
cells. The cells were then grown to 80% confluence  prior to conducting the experiment. On 
the day of the experiment, the media was replaced with 200 μL/well of Opti-MEM® I reduced 
serum medium containing peptides 3 or 4 at 5 μM concentration, and the cells were 
subsequently incubated at 37 °C for 4 h. The cells were subsequently washed, trypsinised, 
stained with trypan blue, and analysed by flow cytometry as described under 4.7.1. 
  
4.7.4 Investigating cell uptake in the presence of excess bombesin peptides 
To further examine the mechanism of cellular uptake, a competative study was performed, 
where an excess of unlabelled bombesin peptides 1 or 2 were added at 50 μM (10× 
concentration) to compete for uptake with the fluorescently-labelled peptides 3 or 4 (at 5 μM) 
respectively. Briefly, PC-3 cells (4 × 10
4 
cells/well) were grown to 80 % confluence in 48 
well plates. The media was then replaced with 200 μL/well Opti-MEM® I reduced serum 
medium and the cells were incubated with a 10× excess of peptides 1 or 2 (to 50 μM final 
concentration) or no peptide (control) for 1 h at 37 °C. Subsequently, fluorophore-labelled 
bombesin peptides 3 or 4 were added (to 5 μM final concentration). The cells were then 
incubated at 37 °C in the dark for 4 h, and subsequently washed, trypsinised, stained with 
trypan blue, and analysed by flow cytometry as described under 4.7.1. 
 
 
 
4.7.5 Confocal microscopy 
The intracellular localisation of fluorophore-labelled bombesin receptor ligand peptides 3 and 
4, after uptake into PC-3 cells, was assessed by confocal microscopy.
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 PC-3 cells were 
seeded at a density of 3 × 10
4
/cm
2
 into ibidi µ-slide  8 well plates. After 24 h, the cells were 
incubated with 5 µM concentration of compounds 3 or 4 in 200 μL/well Opti-MEM® I 
reduced serum medium at 37 °C for 4 h. The cells were then washed 3 times with PBS, 
followed by the addition of Lyso Tracker Red DND 99 (6 µg/mL) for endosome staining and 
Hoechst 33342 (10 nmol/mL) for nuclear staining, followed by incubation at 37 °C for 20 
min. To quench the cell surface fluorescence, the cells were treated with 0.2 % trypan blue 
for 2 min. Finally, the cells were washed  3 times with PBS and covered with complete 
  
 
 
FluoroBrite media. Real time confocal microscopy was then performed on a Zeiss LSM 710 
confocal microscope at 63× magnification using an oil emersion lens. 
 
4.7.6 Statistical Analysis 
Statistical analysis was performed using two-way analysis of variance (ANOVA) followed by 
Tukey’s multiple comparison post hoc test. GraphPad Prism 6 was used for statistial analysis. 
(ns, p > 0.05; *, p  < 0.05; **,p < 0.01; ***, p < 0.0001; ****, p < 0.0001). 
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